Literature DB >> 15981021

Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study.

Paul D Miller1, Stuart L Silverman, Deborah T Gold, Kathleen A Taylor, Peiqi Chen, Rachel B Wagman.   

Abstract

The experience in randomized placebo-controlled clinical trials may differ from that in community practice. The pivotal teriparatide [rhPTH(1-34)] studies were initiated when few therapeutic options for osteoporosis were available. The Direct Analysis of Non-Vertebral Fractures in Community Experience (DANCE) study is a prospective observational trial designed to examine the occurrence of nonvertebral fragility fractures in a large, diverse patient population treated with teriparatide. The occurrence of clinical vertebral fractures and back pain will also be examined, as will bone mineral density, bone mineral content, bone area, safety and tolerability. Subjects will be followed through a course of teriparatide therapy for up to 24 months and for an additional 24 months after cessation of treatment. Therefore, subjects may participate in this study for up to 48 months. DANCE will provide data on the effectiveness and tolerability of teriparatide therapy in clinical practice that will complement the results of published controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15981021     DOI: 10.1007/s00198-005-1915-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  14 in total

1.  Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures.

Authors:  Gordon H Guyatt; Ann Cranney; Lauren Griffith; Stephen Walter; Nicole Krolicki; Murray Favus; Clifford Rosen
Journal:  Endocrinol Metab Clin North Am       Date:  2002-09       Impact factor: 4.741

2.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

3.  Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.

Authors:  D W Dempster; F Cosman; E S Kurland; H Zhou; J Nieves; L Woelfert; E Shane; K Plavetić; R Müller; J Bilezikian; R Lindsay
Journal:  J Bone Miner Res       Date:  2001-10       Impact factor: 6.741

4.  Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.

Authors:  J R Zanchetta; C E Bogado; J L Ferretti; O Wang; M G Wilson; M Sato; G A Gaich; G P Dalsky; S L Myers
Journal:  J Bone Miner Res       Date:  2003-03       Impact factor: 6.741

5.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

Review 6.  The pharmacology of bisphosphonates and new insights into their mechanisms of action.

Authors:  R G Russell; M J Rogers; J C Frith; S P Luckman; F P Coxon; H L Benford; P I Croucher; C Shipman; H A Fleisch
Journal:  J Bone Miner Res       Date:  1999-10       Impact factor: 6.741

7.  Clinical use of teriparatide in the real world: initial insights.

Authors:  Paul D Miller; John P Bilezikian; Chad Deal; Steven T Harris; Roberto Pa Ci
Journal:  Endocr Pract       Date:  2004 Mar-Apr       Impact factor: 3.443

8.  Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.

Authors:  P D Delmas; R R Recker; C H Chesnut; A Skag; J A Stakkestad; R Emkey; J Gilbride; R C Schimmer; C Christiansen
Journal:  Osteoporos Int       Date:  2004-04-08       Impact factor: 4.507

9.  The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

Authors:  E S Orwoll; W H Scheele; S Paul; S Adami; U Syversen; A Diez-Perez; J M Kaufman; A D Clancy; G A Gaich
Journal:  J Bone Miner Res       Date:  2003-01       Impact factor: 6.741

10.  Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.

Authors:  Yebin Jiang; Jenny J Zhao; Bruce H Mitlak; Ouhong Wang; Harry K Genant; Erik F Eriksen
Journal:  J Bone Miner Res       Date:  2003-11       Impact factor: 6.741

View more
  9 in total

1.  Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study.

Authors:  M Wong; X Wan; V Ruff; K Krohn; K Taylor
Journal:  Osteoporos Int       Date:  2011-07-19       Impact factor: 4.507

2.  Repetition of continuous PTH treatments followed by periodic withdrawals exerts anabolic effects on rat bone.

Authors:  Masaya Etoh; Akira Yamaguchi
Journal:  J Bone Miner Metab       Date:  2010-11       Impact factor: 2.626

Review 3.  Osteoporosis therapies: evidence from health-care databases and observational population studies.

Authors:  Stuart L Silverman
Journal:  Calcif Tissue Int       Date:  2010-08-20       Impact factor: 4.333

Review 4.  Teriparatide: a review of its use in osteoporosis.

Authors:  Stephanie K A Blick; Sohita Dhillon; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Safety of parathyroid hormone for the treatment of osteoporosis.

Authors:  Paul D Miller
Journal:  Curr Osteoporos Rep       Date:  2008-03       Impact factor: 5.096

6.  Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.

Authors:  D P Beall; R G Feldman; M L Gordon; B L Gruber; J M Lane; G Valenzuela; D Yim; J Alam; J H Krege; K Krohn
Journal:  Osteoporos Int       Date:  2015-11-10       Impact factor: 4.507

7.  Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational Study.

Authors:  Deborah T Gold; David L Weinstein; Gerhardt Pohl; Kelly D Krohn; Yi Chen; Eric S Meadows
Journal:  J Osteoporos       Date:  2011-10-13

8.  Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis.

Authors:  Robin K Dore
Journal:  Patient Prefer Adherence       Date:  2013-05-20       Impact factor: 2.711

9.  The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results.

Authors:  S Silverman; P Miller; A Sebba; M Weitz; X Wan; J Alam; D Masica; K A Taylor; V A Ruff; K Krohn
Journal:  Osteoporos Int       Date:  2013-02-12       Impact factor: 4.507

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.